An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

News Releases

News Releases from HeadquartersChemical Safety and Pollution Prevention (OCSPP)

EPA Registers First Products to Help Reduce the Spread of Emerging Fungus

Contact Information: 
EPA Press Office (

WASHINGTON Today, the U.S. Environmental Protection Agency announced the availability of 11 products that can be used to disinfect surfaces against an emerging fungus called Candida auris (C. auris). C. auris is an emerging multidrug-resistant fungus that can cause severe infections and spreads easily between hospitalized patients and nursing home residents. The new products EPA is registering provide hospitals and other healthcare facilities with the tools and information needed to help combat this emerging global health threat and help decrease patient infections.

“EPA, together with the Centers for Disease Control and Prevention (CDC) and our other federal partners, play a critical role in ensuring healthcare providers have the latest, most effective products to protect public health, ensure patient safety and save lives,” said Alexandra Dapolito Dunn, assistant administrator for EPA’s Office of Chemical Safety and Pollution Prevention. “Disinfecting surfaces is one of the best ways to stop the spread of C. auris infections, and EPA’s efforts are helping to ensure that healthcare providers have products that can effectively reduce the spread of the dangerous fungus.”

Prior to these 11 products being registered there were no antimicrobial pesticides registered specifically for use against C. auris. EPA worked collaboratively with CDC to ensure product effectiveness against C. auris.   

“The global emergence of C. auris in recent years is concerning for a number of reasons – it causes severe and sometimes deadly illness, it’s very hard to treat, and it’s difficult to prevent it from spreading within healthcare facilities,” said Tom Chiller, MD, chief of CDC’s Mycotic Diseases Branch. “We are encouraged by the progress being made to study new agents and methods for eliminating C. auris from surfaces in healthcare environments, and we need to continue to be vigilant and respond rapidly to be able to control this organism.”

Together both agencies are partnering to reduce the spread of C. auris through rapidly identifying and implementing effective infection control measures. EPA is responsible for regulating hospital disinfectants and provided the test methods and guidance for developing efficacy data against C. auris.

In addition to the new EPA-registered products, disinfectants with an EPA claim for C. difficile (List K) have been used effectively against C. auris. View CDC’s web page on infection prevention and control on what products to use if registered products are unavailable.

View information from EPA on C. auris.

View information from CDC on C. auris.